Thiazolidinedione Therapy for Managing Metabolic Syndrome

MOspace/Manakin Repository

Breadcrumbs Navigation

Thiazolidinedione Therapy for Managing Metabolic Syndrome

Please use this identifier to cite or link to this item:

[-] show simple item record Geurin, Michael D. St. Anna, Leilani 2011-10-21T18:35:44Z 2011-10-21T18:35:44Z 2010-12 eng
dc.identifier.citation American Family Physician, 82(128) 2010: [1553]-1554. en_US
dc.description.abstract There is no patient-oriented evidence supporting the use of TZD therapy in patients in the general population who have metabolic syndrome. Rosiglitazone (Avandia) use decreases cardiovascular morbidity and mortality in patients with metabolic syndrome who are undergoing coronary stenting. (Strength of Recommendation: B, based on a single randomized controlled trial). Effects of TZD therapy on nonglycemic markers of metabolic syndrome are inconsistent compared with the effects of other hypoglycemic medications. en_US
dc.language.iso en_US en_US
dc.publisher Family Physicians Inquiries Network en_US
dc.relation.ispartof Clinical Inquiries, 2010 (MU) en
dc.subject cardiac events en_US
dc.subject preventative measures en_US
dc.subject.lcsh Cardiovascular emergencies en_US
dc.title Thiazolidinedione Therapy for Managing Metabolic Syndrome en_US
dc.type Article en_US
dc.relation.ispartofcommunity University of Missouri-Columbia. School of Medicine. Department of Family and Community Medicine. Family Physicians Inquiries Network

This item appears in the following Collection(s)

[-] show simple item record